Overview

Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to describe the long-term safety and efficacy of etelcalcetide (AMG 416) for the treatment of SHPT in adults with CKD on hemodialysis.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen